GlassScriptPhysician profile
Daniel D Elsholz
NPI 1902847122
$3,010.22
in general payments reported to CMS, 2019-2025
26 companies · $760 in 2025
The $760 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $181 · 2021: $146 · 2022: $465 · 2023: $759 · 2024: $447 · 2025: $760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $720.89 | 2022-2025 | Minimed 780g, Minimed 770g |
| Insulet Corporation | $474.30 | 2019-2025 | Omnipod |
| Dexcom, INC. | $412.81 | 2019-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $192.95 | 2019-2025 | |
| Novo Nordisk INC | $173.74 | 2019-2025 | Sogroya |
| Azurity Pharmaceuticals, INC. | $162.03 | 2023-2025 | Triptodur, Triptodur |
| Tandem Diabetes Care, INC. | $123.88 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Eton Pharmaceuticals, INC. | $86.71 | 2025 | Increlex, Alkindi, Khindivi |
| Medtronic Minimed, INC. | $82.68 | 2019-2020 | |
| Abbott Laboratories | $73.69 | 2022-2023 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $58.09 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $56.45 | 2019-2020 | |
| Qol Medical, LLC | $47.67 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $45.37 | 2023 | Gvoke Hypopen |
| Soleno Therapeutics, INC. | $39.99 | 2025 | Vykat Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32.56 | 2019-2021 | |
| Sobi, INC | $31.22 | 2022 | |
| Mannkind Corporation | $23.48 | 2023 | Afrezza |
| Arbor Pharmaceuticals, INC. | $22.74 | 2019-2020 | |
| Lilly USA, LLC | $22.34 | 2020 | |
| Sanofi-Aventis U.S. LLC | $22.24 | 2025 | |
| Tolmar, INC. | $22.11 | 2025 | Fensolvi |
| Beta Bionics, INC. | $21.37 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $21.14 | 2025 | Twiist |
| Endo Pharmaceuticals INC. | $20.57 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $19.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Elsholz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.